Funding Successes

2025 - 2030

PIs: Singh SS, Tsang B, Co-Is: Cook D, Mer A, Asare-Werehene M, Gale J, Flaxman TE, Maheux-Lacroix S, Yong P, Gandhi A, Wren J, Collaborator: Etowa J. Ethnic and racial disparity in endometriosis pathobiology, diagnosis, and treatment. Project Grant, Canadian Institutes of Health Research, $1,055,700 CAD

2025 - 2028

PI: Gale G, Co-Is: Singh SS (Mentor), Wu C, AlSalem H, Flaxman T, Corsini-Munt S, Ramsay T, El-Chaar D; Collaborators: Cayer S, Brubacher E. The impact of endometriosis on the IVF patient: prevalence, quality of life and pregnancy outcomes. New Investigator Clinical Grant, PSI Foundation, $300,000 CAD

2023 - 2025

PIs: Corsini-Munt S, Singh SS; Co-Is: Flaxman TE, Horwood G, Gates-Mackinnon J, Stragapede E. Informing Care by understanding the association between chronic pelvic pain and interpersonal trauma through patient and provider narratives: A mixed-methods study to improve clinical gynecologic care. Canadian Institutes of Health Research (CIHR), $100,000CAD

2023 - 2025

PI: Gale J, Co-Is: Singh SS, Flaxman TE, Graham I, Cayer S, Morisette C, Wu C, Della Zazzera V, Brubacher. A prospective single site study of the effectiveness of Assessment of Sonographic Suggestion of Endometriosis via Soft Signs among Fertility patients (ASSESS Study). Canadian Society for the Advancement of Gynecologic Excellence (CanSAGE), $30,000CAD

2022 - 2025

PIs: Singh SS, Aviv R, Co-Is: Flaxman TE, Carrington A, Duigenan S, McInnes M, Miguel O. Artificial intelligence applied to three-dimensional (3D) rendered models from MR imaging: Optimizing preoperative planning and surgical outcomes in patients with uterine fibroids. The Ottawa Hospital Academic Medical Organization (TOHAMO), $100,000CAD

2021 - 2025

PI: Singh SS, Co-Is: McLean L, della Zazzera V, McInnes M, Wen SW, Strickland S, Labrosse M, Flaxman TE, Czyrnyj C. Characterisation of tissue stiffness to improve the diagnosis and management of uterine fibroids: The use of shearwave elastography to stratify treatment. Physicians Services Incorporated Foundation (PSI) Health Research Grant, $250,000CAD

2026 - 2027

Principal Investigator (Site). Clinical Trial: Bayer 22923 – A multi-center, open-label, randomized parallel group study evaluating the proportion of women with complete resolution of nonatypical endometrial hyperplasia when treated with Mirena or oral Medroxyprogesterone acetate for 6 months. Bayer Inc Clinical Trial, $393,929CAD

2025 - 2035

Principal Investigator (Canadian Coordinating Centre). Clinical Registry: AbbVie P22-392 - The Ubrelvy and Qulipta Pregnancy Exposure Registry (EMPRESS): An Observational Prospective Study to Assess the Safety of Ubrelvy (ubrogenant) and Qulipta (atogenant) During Pregnancy. AbbVie Canada, ~$150,000CAD

2023 - 2025

Principal Investigator (Site). Clinical Trial: Bayer 21656 - To investigate efficacy and safety of elinzanetant for the treatment of VMS caused by adjuvant endocrine therapy, over 52 weeks in women with, or at high risk for developing hormone-receptor positive breast cancer. Bayer Inc Clinical Trial, $325,228CAD

2021 - 2025

Principal Investigator (Site). Validation of specific biomarkers for the diagnosis of endometriosis (EndoSearch), EndoDiag Clinical Research, $51,881CAD.

2022 - 2024

Principal Investigator (Site). Clinical Trial: Bayer 21810 - A double-blind, randomized, placebo controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women, Bayer Inc Clinical Trial, $211,642CAD